Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial

K. Fizazi,P. Gonzalez Mella,D. Castellano,J. N. Minatta,A. R. Kalebasty, D. Shaffer, J. C. Vazquez Limon, H. M. Sanchez Lopez,A. J. Armstrong, L. Horvath,D. A. Bastos,N. P. Amin,J. Li,K. Unsal-Kacmaz,M. Retz,F. Saad,D. P. Petrylak,R. K. Pachynski

European Journal of Cancer（2023）

引用 27|浏览14

暂无评分

摘要

•Nivolumab plus docetaxel has clinical activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.•Safety of the combination is consistent with that of the individual components.•These data support further investigation in the ongoing phase III CheckMate 7DX trial.

查看译文

关键词

Clinical trial,Docetaxel,Metastatic castration-resistant prostate cancer,Nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要